TY - JOUR
T1 - Pharmacogenomics of HIV therapy
T2 - Summary of a workshop sponsored by the National Institute of allergy and infectious diseases
AU - Haas, David
AU - Kuritzkes, Daniel
AU - Ritchie, Marylyn
AU - Amur, Shashi
AU - Gage, Brian
AU - Maartens, Gary
AU - Masys, Dan
AU - Fellay, Jacques
AU - Phillips, Elizabeth
AU - Ribaudo, Heather
AU - Freedberg, Kenneth
AU - Petropoulos, Christos
AU - Manolio, Teri
AU - Gulick, Roy
AU - Haubrich, Richard
AU - Kim, Peter
AU - Dehlinger, Marjorie
AU - Abebe, Rahel
AU - Telenti, Amalio
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Approximately 1 million people in the United States and over 30 million worldwide are living with human immunodefi ciency virus type 1 (HIV-1). While mortality from untreated infection approaches 100%, survival improves markedly with use of contemporary antiretroviral therapies (ART). In the United States, 25 drugs are approved for treating HIV-1, and increasing numbers are available in resource-limited countries. Safe and effective ART is a cornerstone in the global struggle against the acquired immunodefi ciency syndrome. Variable responses to ART are due at least in part to human genetic variants that affect drug metabolism, drug disposition, and off-site drug targets. Defi ning effects of human genetic variants on HIV treatment toxicity, effi cacy, and pharmacokinetics has far-reaching implications. In 2010, the National Institute of Allergy and Infectious Diseases sponsored a workshopentitled,Pharmacogenomics A Path Towards Personalized HIV Care. This article summarizes workshop objectives, presentations, discussions, and recommendations derived from this meeting.
AB - Approximately 1 million people in the United States and over 30 million worldwide are living with human immunodefi ciency virus type 1 (HIV-1). While mortality from untreated infection approaches 100%, survival improves markedly with use of contemporary antiretroviral therapies (ART). In the United States, 25 drugs are approved for treating HIV-1, and increasing numbers are available in resource-limited countries. Safe and effective ART is a cornerstone in the global struggle against the acquired immunodefi ciency syndrome. Variable responses to ART are due at least in part to human genetic variants that affect drug metabolism, drug disposition, and off-site drug targets. Defi ning effects of human genetic variants on HIV treatment toxicity, effi cacy, and pharmacokinetics has far-reaching implications. In 2010, the National Institute of Allergy and Infectious Diseases sponsored a workshopentitled,Pharmacogenomics A Path Towards Personalized HIV Care. This article summarizes workshop objectives, presentations, discussions, and recommendations derived from this meeting.
UR - http://www.scopus.com/inward/record.url?scp=84255190568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84255190568&partnerID=8YFLogxK
U2 - 10.1310/hct1205-277
DO - 10.1310/hct1205-277
M3 - Article
C2 - 22180526
AN - SCOPUS:84255190568
SN - 2578-7489
VL - 12
SP - 277
EP - 285
JO - HIV Research and Clinical Practice
JF - HIV Research and Clinical Practice
IS - 5
ER -